TABLE 8, Adalimumab: summary of main results - Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation

Outcome	3 months	6 months	≥ 9 months
Withdrawals (%):
for any reason	9.8–9.9	0	12.5–26.8
due to lack of efficacy	2.9	0	8.3–17.1
due to AEs	5.6	0	8.3–14.6
ACR20 response (%)	46.3–60.1	70.4	75.0
ACR50 response (%)	26.8–33.0	NR	50.0
ACR70 response (%)	12.2–13.0	NR	33.3
EULAR response (%):
good/moderate response	76.0–78.0	65.4	70.8
good response	17.1–23.0	19.2	NR
remission	NR	7.7	NR
DAS28:
mean change from baseline	−1.50 to −1.90 (significant improvement)	−1.30 to −1.70 (significant improvement)	NR
mean at time point	4.50	4.20	3.20
HAQ: mean change from baseline	−0.21 to −0.48 (significant improvement)	−0.31 (significant improvement)	NR
QoL	NR	NR	NR
Joint damage	NR	NR	NR
Serious AEs	From one study:⁹⁵^,⁹⁶ 18% had serious AE (no lupus-related or demyelinating disorder) and 13% withdrew because of AE	NR	NR
Any infections/serious infections	From one study:⁹⁵^,⁹⁶ serious infections rate 10.0/100 patient years; TB infection rate 0.4/100 patient-years	NR	From one study:⁹⁷ one patient developed pulmonary TB; one with serious cellulitis From one study:⁹⁴ one herpes zoster infection led to withdrawal
Infusion reaction	From one study:⁹⁵^,⁹⁶ allergic AEs 6.5/100 patient-years (no serious anaphylactic response)	NR	From one study:⁹⁴ one withdrawal because of an immediate hypersensitivity reaction

Outcome

3 months

6 months

≥ 9 months

Withdrawals (%):

for any reason

9.8–9.9

12.5–26.8

due to lack of efficacy

2.9

8.3–17.1

due to AEs

5.6

8.3–14.6

ACR20 response (%)

46.3–60.1

70.4

75.0

ACR50 response (%)

26.8–33.0

50.0

ACR70 response (%)

12.2–13.0

33.3

EULAR response (%):

good/moderate response

76.0–78.0

65.4

70.8

good response

17.1–23.0

19.2

remission

7.7

DAS28:

mean change from baseline

−1.50 to −1.90 (significant improvement)

−1.30 to −1.70 (significant improvement)

mean at time point

4.50

4.20

3.20

HAQ: mean change from baseline

−0.21 to −0.48 (significant improvement)

−0.31 (significant improvement)

QoL

Joint damage

Serious AEs

From one study:⁹⁵^,⁹⁶ 18% had serious AE (no lupus-related or demyelinating disorder) and 13% withdrew because of AE

Any infections/serious infections

From one study:⁹⁵^,⁹⁶ serious infections rate 10.0/100 patient years; TB infection rate 0.4/100 patient-years

From one study:⁹⁷ one patient developed pulmonary TB; one with serious cellulitis

From one study:⁹⁴ one herpes zoster infection led to withdrawal

Infusion reaction

From one study:⁹⁵^,⁹⁶ allergic AEs 6.5/100 patient-years (no serious anaphylactic response)

From one study:⁹⁴ one withdrawal because of an immediate hypersensitivity reaction

From: 3, Assessment of clinical effectiveness

Cover of Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation

Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation.

Health Technology Assessment, No. 15.14.

Malottki K, Barton P, Tsourapas A, et al.

Southampton (UK): NIHR Journals Library; 2011 Mar.

Included under terms of UK Non-commercial Government License.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

TABLE 8Adalimumab: summary of main results